ADAXION is developing innovative treatments for immune-mediated and inflammatory diseases using its proprietary ADAx platform. This technology is designed to deimmunize protein therapeutics—preventing the formation of anti-drug antibodies (ADAs) that can compromise efficacy and trigger harmful immune responses.

ADAXION Therapeutics

Founded: 2020
Location: San Diego, CA
Employee range: 11-50
Funding: not disclosed

Temporary Senior Research Associate - Protein Purification and Bioconjugation (Contract Position)

Our June ADAXION team happy hour was in celebration of Jim Paulson and his retirement from Scripps. We are incredibly grateful for his breakthroughs in Siglec biology that laid the foundation for ADAXION and for his ongoing contributions on our scientific advisory board. We wish him a much-deserved and restful retirement! 

Learn more about our company and its culture: www.adaxiontx.com

ADAXION Technology Spotlight: 

At ADAXION, we’re redefining biologic drug design with our ADAx platform, a technology that suppresses immunogenicity by engaging natural immune regulatory pathways. Specifically, ADAx co-engages CD22 and the B cell receptor to suppress immune responses against therapeutics. Our proprietary CD22 ligands enable targeted B cell inhibition without compromising normal immunity, offering a versatile solution across diverse protein formats. 

Discover more about the science behind our platform: adaxiontx.com/technology 

Welcome to the official ADAXION Therapeutics LinkedIn company page!

We’re working on solving the immunogenicity challenge by unlocking the full potential of biologic therapies. Follow us to stay updated on innovations, team wins, and thought leadership. 

Learn more: adaxiontx.com/technology/

ADAXION Therapeutics

Business:

About: